The combination therapy (ICG-PDT-based combination with dual-ICI therapy (anti-CTLA4 and anti-PD-L1)) resulted in the strongest tumor growth inhibition and the highest percentage of tumor-free survival rate (62.5%). The gene discussed is CD274; the disease is neoplasm.